Semaglutide, a GLP-1 receptor agonist, is known for its ability to help suppress appetite and support healthy weight loss
How This Compares to Similar Drugs Tirzepatide's Phase 3 trials began in 2019, FDA submission happened in mid-2022, and approval came in May 2022 (for diabetes) and November 2023 (for obesity)
This review typically takes 6-12 months after Health Canada approval
The Medicines and Healthcare products Regulatory Agency (MHRA), which is responsible for licensing medicines in the UK, has not granted approval for retatrutide
Le Dr David Lau, endocrinologue praticien et professeur mrite de mdecine, de biochimie et de biologie molculaire l'cole de mdecine Cumming de l'Universit de Calgary, abonde dans le mme sens
Even 30 minutes a day can make a difference